252 reports of this reaction
1.8% of all PRASUGREL HYDROCHLORIDE reports
#12 most reported adverse reaction
EPISTAXIS is the #12 most commonly reported adverse reaction for PRASUGREL HYDROCHLORIDE, manufactured by Cosette Pharmaceuticals, Inc.. There are 252 FDA adverse event reports linking PRASUGREL HYDROCHLORIDE to EPISTAXIS. This represents approximately 1.8% of all 14,129 adverse event reports for this drug.
Patients taking PRASUGREL HYDROCHLORIDE who experience epistaxis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPISTAXIS is a less commonly reported adverse event for PRASUGREL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to epistaxis, the following adverse reactions have been reported for PRASUGREL HYDROCHLORIDE:
The following drugs have also been linked to epistaxis in FDA adverse event reports:
EPISTAXIS has been reported as an adverse event in 252 FDA reports for PRASUGREL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPISTAXIS accounts for approximately 1.8% of all adverse event reports for PRASUGREL HYDROCHLORIDE, making it a notable side effect.
If you experience epistaxis while taking PRASUGREL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.